169 related articles for article (PubMed ID: 23635475)
1. MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm.
Ohira G; Kimura K; Yamada N; Amano R; Nakata B; Doi Y; Murata A; Yashiro M; Tanaka S; Ohsawa M; Wakasa K; Hirakawa K
Hepatogastroenterology; 2013; 60(125):1067-72. PubMed ID: 23635475
[TBL] [Abstract][Full Text] [Related]
2. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
[TBL] [Abstract][Full Text] [Related]
3. Molecular profile of apomucin and p53 protein as predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
Mizumoto M; Honjo G; Kobashi Y; Awane M; Matsusue S
Hepatogastroenterology; 2011; 58(110-111):1791-5. PubMed ID: 22086702
[TBL] [Abstract][Full Text] [Related]
4. The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas.
Kanno A; Satoh K; Kimura K; Hirota M; Umino J; Masamune A; Satoh A; Asakura T; Egawa S; Sunamura M; Endoh M; Shimosegawa T
Pancreas; 2006 Nov; 33(4):391-6. PubMed ID: 17079945
[TBL] [Abstract][Full Text] [Related]
5. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
6. Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
Takahashi H; Nakamori S; Nakahira S; Tsujie M; Takahshi Y; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Ann Surg Oncol; 2006 Jul; 13(7):955-60. PubMed ID: 16788757
[TBL] [Abstract][Full Text] [Related]
7. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
[TBL] [Abstract][Full Text] [Related]
8. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm.
Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
Ann Surg Oncol; 2014 Jul; 21(7):2444-52. PubMed ID: 24562937
[TBL] [Abstract][Full Text] [Related]
9. Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.
Kucera S; Centeno BA; Springett G; Malafa MP; Chen YA; Weber J; Klapman J
JOP; 2012 Jul; 13(4):409-13. PubMed ID: 22797397
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
[TBL] [Abstract][Full Text] [Related]
11. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
[TBL] [Abstract][Full Text] [Related]
12. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
13. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival.
Raut CP; Cleary KR; Staerkel GA; Abbruzzese JL; Wolff RA; Lee JH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2006 Apr; 13(4):582-94. PubMed ID: 16523362
[TBL] [Abstract][Full Text] [Related]
14. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas.
Kang KM; Lee JM; Shin CI; Baek JH; Kim SH; Yoon JH; Han JK; Choi BI
J Magn Reson Imaging; 2013 Sep; 38(3):555-63. PubMed ID: 23390008
[TBL] [Abstract][Full Text] [Related]
15. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
[TBL] [Abstract][Full Text] [Related]
16. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive intraductal papillary mucinous neoplasms and mucinous cystic neoplasms: recurrence rates and postoperative imaging follow-up.
Xourafas D; Tavakkoli A; Clancy TE; Ashley SW
Surgery; 2015 Mar; 157(3):473-83. PubMed ID: 25596773
[TBL] [Abstract][Full Text] [Related]
18. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain.
Hara T; Ikebe D; Odaka A; Sudo K; Nakamura K; Yamamoto H; Itami M; Hirata T; Kashimura J; Yamaguchi T
Ann Surg; 2013 Jun; 257(6):1103-11. PubMed ID: 23364699
[TBL] [Abstract][Full Text] [Related]
19. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
20. Invasive IPMN and MCN: same organ, different outcomes?
Kargozaran H; Vu V; Ray P; Bagaria S; Steen S; Ye X; Gagandeep S
Ann Surg Oncol; 2011 Feb; 18(2):345-51. PubMed ID: 20809175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
